DV
Dividend Vision

ABP — Abpro Holdings, Inc.

Abpro Holdings, Inc. (ABP)

Total return is -97.9% over the past 4.4 years, 190.9 points behind SPY at 93.0%. Its deepest 1-year drawdown was 98.8%.

Abpro Holdings is a biotechnology company developing novel antibody constructs for immuno-oncology and ophthalmology applications, leveraging its DiversImmune discovery platform and MultiMab engineering platform to create multi-specific antibodies. The company does not currently distribute dividends. Abpro appeals to investors seeking exposure to early-stage biotech with a focus on immuno-oncology and eye disease treatments.

ABP key facts

Asset type
Stock
Asset class
Equity
Inception date
03/09/2022
Last close
$6.10
Market cap
$1,417,897
Average volume
9750.0
Beta
-0.004
Payout ratio
0.0
Forward P/E
0.0
EPS
$-8.25